GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,400.00p
   
  • Change Today:
    -2.50p
  • 52 Week High: 1,671.00
  • 52 Week Low: 1,264.00
  • Currency: UK Pounds
  • Shares Issued: 4,092.07m
  • Volume: 2,742,199
  • Market Cap: £57,289m
  • RiskGrade: 129

Latest ShareCast News

EMA accepts marketing authorisation application for GSK's linerixibat

By Josh White

Date: Monday 23 Jun 2025

(Sharecast News) - GSK said on Monday that the European Medicines Agency has accepted its marketing authorisation application for linerixibat, an investigational treatment for cholestatic pruritus in patients with primary biliary cholangitis (PBC).

GSK ShareCast News

GSK hoping to expand Arexvy usage in Japan 20-Jun-2025 ShareCast
GSK's RSV vaccine accepted for regulatory review... 13-Jun-2025 ShareCast
Berenberg downgrades GSK to 'hold' ahead of prod... 03-Jun-2025 ShareCast
GSK's linerixibat to be reviewed by US FDA 02-Jun-2025 ShareCast
GSK, Spero UTI drug trial ends early after meeti... 28-May-2025 ShareCast

GSK Regulatory News

Director/PDMR Shareholding 23-Jun-2025 15:30 RNS
Replacement RNS: Linerixibat file accepted by EMA 23-Jun-2025 08:30 RNS
GSK Submits Arexvy for adults 18+ with EMA 23-Jun-2025 08:18 RNS
Transaction in Own Shares 23-Jun-2025 07:00 RNS
Arexvy filed in Japan for 18-49 at increased risk 20-Jun-2025 07:00 RNS

GSK Newspaper Links

GlaxoSmithKline scraps sale of old drugs 05-Dec-2014 Telegraph
Glaxo sharpens axe to save £1bn as insurers and ... 01-Dec-2014 The Independent
GSK to cut hundreds of US jobs 01-Dec-2014 Telegraph
Ebola vaccine trials 'encouraging', says GSK 27-Nov-2014 Telegraph
GlaxoSmithKline tops table in effort to get drug... 17-Nov-2014 Guardian

GSK Tips & Analysis

Questor :GlaxoSmithKline 16-Apr-2014 Telegraph
Questor:GlaxoSmithKline 06-Oct-2011 Telegraph
Questor:GlaxoSmithKline 11-Aug-2011 Telegraph
Questor tip: GlaxoSmithKline 28-Jul-2011 Telegraph
Investment Column: GlaxoSmithKline 27-Jul-2011 The Independent

GSK News Wires

FDA Approves Promacta(R) (Eltrombopag), the Firs... 20-Nov-2008 PR Newswire
Study Found That Long Term Use of Advair Diskus(... 29-Oct-2008 PR Newswire
GlaxoSmithKline to Acquire Genelabs Technologies... 29-Oct-2008 PR Newswire
A New Interactive Consumer Experience Highlighti... 28-Sep-2007 PR Newswire
AUDIO from Medialink and GlaxoSmithKline: A New ... 28-Sep-2007 PR Newswire

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,400.00p
Change Today -2.50p
% Change -0.18 %
52 Week High 1,671.00
52 Week Low 1,264.00
Volume 2,742,199
Shares Issued 4,092.07m
Market Cap £57,289m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
47.79% below the market average47.79% below the market average47.79% below the market average47.79% below the market average47.79% below the market average
39.13% above the sector average39.13% above the sector average39.13% above the sector average39.13% above the sector average39.13% above the sector average
Price Trend
7.48% above the market average7.48% above the market average7.48% above the market average7.48% above the market average7.48% above the market average
52.17% above the sector average52.17% above the sector average52.17% above the sector average52.17% above the sector average52.17% above the sector average
Income
73.31% above the market average73.31% above the market average73.31% above the market average73.31% above the market average73.31% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
33.33% below the market average33.33% below the market average33.33% below the market average33.33% below the market average33.33% below the market average
41.94% below the sector average41.94% below the sector average41.94% below the sector average41.94% below the sector average41.94% below the sector average

What The Brokers Say

Strong Buy 4
Buy 2
Neutral 14
Sell 3
Strong Sell 1
Total 24
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q1 Q4
Ex-Div 15-May-25 20-Feb-25
Paid 10-Jul-25 10-Apr-25
Amount 16.00p 16.00p

Trades for 23-Jun-2025

Time Volume / Share Price
15:28 0 @ 1,400.50p
15:28 1,200 @ 1,400.00p
15:28 114 @ 1,400.00p
15:28 242 @ 1,400.00p
15:28 236 @ 1,400.35p

GSK Key Personnel

CEO Emma Walmsley

Top of Page